Please assess the completion status of the following clinical trial:

Trial Title: Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients are included in the study if all of the following criteria are met:~* Written informed consent is obtained.~* The patient is an outpatient, man or woman of any ethnic origin, 18 to 65 years of age (inclusive).~* The patient has a complaint of excessive sleepiness.~* The patient has a diagnosis of SWSD according to International Classification of Sleep Disorders (ICSD) criteria, and must have had excessive sleepiness during night shifts for at least 3 months.~* The patient must work at least 5 night shifts per month, of which at least 3 nights are consecutive, and plan to maintain this schedule.~* The patient must work night shifts that include at least 6 hours between 2200 and 0800 and be no longer than 12 hours in duration.~* The patient is in good health as determined by a medical and psychiatric history, physical examination, ECG, and serum chemistry and hematology.~* Women must be surgically sterile, 2 years postmenopausal, or, if of child-bearing potential, using a medically accepted method of birth control (ie, barrier method with spermicide, steroidal contraceptive, or intrauterine device \[IUD\]) and agree to continued use of this method for the duration of the study. Steroidal contraceptives must be used with a barrier method while taking the study drug and for at least a full cycle after discontinuation of the study drug.~* The patient has a mean sleep latency of 6 minutes or less as determined by the MSLT~* The patient has a CGI-S rating as it pertains to sleepiness during night shifts including the commute to and from work.~* The patient does not have any medical or psychiatric disorders that could account for the excessive sleepiness during the night shift.~* The patient is able to complete self rating scales and computer-based testing.~* The patient is willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol.~Exclusion Criteria:~Patients are excluded from participating in this study if 1 or more of the following criteria are met:~* has any clinically significant, uncontrolled medical or psychiatric conditions (treated or untreated)~* has a probable diagnosis of a current sleep disorder other than SWSD~* consumes caffeine including coffee, tea and/or other caffeine containing beverages or food averaging more than 600 mg of caffeine per day~* used any prescription drugs disallowed by the protocol or clinically significant use of over the-counter (OTC) drugs within 7 days before the screening/baseline visit~* has a history of alcohol, narcotic, or any other drug abuse as defined by the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, 4th Edition (DSM IV)~* has a positive urine drug screen (UDS) at the screening visit~* has a clinically significant deviation from normal in the physical examination~* is a pregnant or lactating woman. (Any woman becoming pregnant during the study will be withdrawn from the study.)~* has used an investigational drug within 1 month before the screening visit~* has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery)~* has a known clinically significant drug sensitivity to stimulants or modafinil

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Armodafinil 150 mg/day
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).